Homozygous arginine-72 in wild type p53 and risk of cervical cancer

Lancet

Volumn 352, Issue 9142, 1998, Pages 1756-

  Hayes, Vanessa M ^b   Hofstra, Robert M W ^b   Buys, Charles H C M ^b   Hollema, Harry ^b   Van Der Zee, Ate G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER RISK; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; NORMAL HUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

EID: 0032576390     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)79829-9     Document Type: Article

References (5)

1. 1 Matlashewski GJ, Tuck S, Pim D, et al. Primary structure polymorphism at amnio acid residue 72 of human p53. Mol Cell Biol 1987; 7: 961-63.
2. 2 Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-33.
3. 3 Beckman G, Birgander R, Sjalander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44: 266-70.
4. 4 To-Figueras J, Gene M, Gomez-Catalan J, et al. Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1996; 5: 337-42.
5. 5 Rosenthal AN, Ryan A, Al-Jehani RM, et al. P53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998; 352: 871-75.